Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64 (faCTor-64)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Deseret Foundation
Toshiba America Medical Systems, Inc.
Information provided by (Responsible Party):
Intermountain Health Care, Inc.
ClinicalTrials.gov Identifier:
NCT00488033
First received: June 15, 2007
Last updated: August 2, 2013
Last verified: August 2013

June 15, 2007
August 2, 2013
June 2007
June 2014   (final data collection date for primary outcome measure)
The combination of all cause death, non-fatal MI, and hospitalization for unstable angina. [ Time Frame: 2-years ] [ Designated as safety issue: No ]
The combination of all cause death, non-fatal MI, and hospitalization for unstable angina. [ Time Frame: 2-years ]
Complete list of historical versions of study NCT00488033 on ClinicalTrials.gov Archive Site
1. CV death 2. Hospitalization for heart failure 3. Worsening renal failure (progression of serum creatinine by ≥0.5 mg/dL 4. Stroke or carotid revascularization procedure 5. Limb amputation or peripheral vascular disease [ Time Frame: 2-years ] [ Designated as safety issue: No ]
1. Cardiovascular death 2. Hospitalization for congestive heart failure 3. Worsening renal failure (defined as progression of serum creatinine by ≥0.5 mg/dL 4. Stroke or carotid revascularization procedure 5. Limb amputation or peripheral vascul [ Time Frame: 2-years ]
Not Provided
Not Provided
 
Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64: A Randomized Control Study (The faCTor-64 Study)

Patients with a known history of diabetes mellitus and no prior documented evidence of cardiovascular disease will be evaluated for inclusion in the study. Once qualified, patients will be enrolled and be randomized to either the Control Arm or to the Asymptomatic Screening Arm. Patients in the Control Arm will be followed by their primary care physicians with the recommendation that they follow standard guidelines for management of diabetic patients.

Patients in the Asymptomatic Screening Arm will undergo CT screening for either coronary calcium scoring or multi-slice CT angiography as well as be placed on one of two medical regimens. Patients will be followed by telephone at six-month intervals for two years for both primary and secondary outcomes.

Management of Patients Randomized to the Control Arm: Subjects randomized to the control arm will continue to be followed by their primary care physicians with the recommendation that they follow standard guidelines for management of diabetic patients.

Management of Patients Randomized to the Asymptomatic Screening Arm: Subjects randomized to the Asymptomatic Screening arm will undergo initial CT screening in the following fashion:

  • Subjects with serum creatinine of < 2.0 mg/dl (men) or <1.8 mg/dL (women) will be screened using multi-slice CT angiography with contrast.
  • Those with serum creatinine ≥ 2.0 mg/dl (men) or >1.8 mg/dL (women) will be screened without contrast to obtain a coronary calcium score. Further cardiac screening will be determined based on these results.

Subjects Receiving Multi-Slice CT Angiography (serum creatinine of < 2.0 mg/dl (men) or <1.8 mg/dL (women)): Subjects severe stenosis will proceed to coronary angiography and revascularization as needed. Subjects with moderate stenosis will be referred for adenosine stress cardiac MRI. If ischemia is detected, they will also be referred for coronary angiography. Subjects with either mild stenosis or normal coronary arteries will receive no further imaging studies.

Subjects Undergoing CT Evaluation for Coronary Calcium Scoring (serum creatinine ≥ 2.0 mg/dl (men) or >1.8 mg/dL (women): Subjects with coronary calcium scores >100 or >75th percentile will be referred for adenosine stress cardiac MRI. If ischemia is detected, they will be referred for coronary angiography. Subjects with coronary calcium scores = 0-10 or 11-100 and <75th percentile will receive no further imaging studies.

Medical Management (Only for those patients randomized to the Asymptomatic Screening Arm): In addition to the imaging studies and potential coronary revascularization procedures performed as described above, all subjects will be placed on one of two medical regimens:

  • Standard Appropriate DM Care and
  • Aggressive Risk Factor Reduction Care.

Standard Appropriate DM Care: Subjects assigned to this form of medical care will be managed by their primary physicians. This type of care will consist of targeting the goals proposed by Intermountain Healthcare for all patients with diabetes. These include the following three targets: HgA1C <7.0%, LDL cholesterol <100 mg/dL and Systolic BP<130 mm Hg. Subjects assigned to Standard Care will include all control subjects, as well as all screened subjects with either a normal CT angiogram or a coronary calcium score = 0-10.

Aggressive Risk Factor Reduction Care: Subjects assigned to this form of medical care, in addition to standard medical care provided by their primary physicians, will also be managed by their primary physicians, but will receive more aggressive risk factor reduction management according to a set of guidelines that will be given to the primary physicians. This aggressive management strategy, designed to address the increased medical risk among the asymptomatic diabetics with detected vascular disease, will consist of more aggressive glucose and lipid targets than is in the Standard Care protocols and specific medication algorithms designed to accomplish these more aggressive targets.

Follow-Up After enrollment into the protocol, all subjects will be followed for two years. Follow-up will occur by telephone at six-month intervals. Outcomes will be ascertained by directly questioning the patient and by review of medical records. All primary outcomes will be adjudicated by an independent events committee. At 24 months, the SF-12 questionnaire will be mailed to all the participants to determine their physical and mental status.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Prevention
Coronary Artery Disease
Procedure: CT Angiography
If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
  • No Intervention: 1
    Standard of Care
  • 2
    CT Angiography
    Intervention: Procedure: CT Angiography
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1100
December 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age: Males ≥ 50 years; Females ≥55 years with: History of diabetes mellitus (prior documentation of fasting glucose ≥ 126 mg/dl or hemoglobin A1C > 6.5%), either type 1 or type 2, documented for at least 3 years and on medication for at least one year.
  2. Age: Males ≥ 40 years; Females ≥45 years with: History of diabetes mellitus (prior documentation of fasting glucose ≥ 126 mg/dl or hemoglobin A1C > 6.5%), either type 1 or type 2, documented for at least 5 years and on medication for at least one year.
  3. The patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board.

Exclusion Criteria:

  1. Known coronary artery disease (stenosis >70%, history of myocardial infarction, or angina)
  2. Symptomatic cerebral vascular disease (history of TIA, CVA, or cerebrovascular [carotid or cerebral arteries] revascularization)
  3. Symptomatic peripheral vascular disease (history of claudication, amputation, or peripheral [including renal arteries] arterial revascularization)
  4. Treatment with any other investigational drug within the previous 30 days
  5. Any therapy or condition that would pose a risk to the patient or make it difficult to comply with study requirements.
  6. Pregnant and/or lactating women, and women of child bearing potential not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.
  7. Any life threatening condition/significant co-morbidity such that primary screening is inappropriate.

    -

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00488033
128-026
Yes
Intermountain Health Care, Inc.
Intermountain Health Care, Inc.
  • Deseret Foundation
  • Toshiba America Medical Systems, Inc.
Principal Investigator: Joseph B Muhlestein, MD Intermountain Health Care, Inc.
Intermountain Health Care, Inc.
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP